Nathalie Adda named Enanta CMO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.

Nathalie Adda named Enanta CMO

Enanta Pharmaceuticals
Dr. Nathalie Adda was named CMO.

Dr. Nathalie Adda was named CMO of Enanta Pharmaceuticals ($ENTA) this week as the company prepares to advance its internal virology and liver disease programs. Adda has more than 15 years of experience in the pharma industry, serving in all phases of global clinical research and development and commercialization, Enanta said in its statement, most recently as the CMO at Transgene. From 2006 to 2012, Adda was senior medical director for the Incivek clinical program at Vertex ($VRTX), where she designed Phase II and Phase III trials. She's also held research positions at Gilead ($GILD), Triangle Pharmaceuticals and Boehringer Ingelheim. Release


Editas taps Andrew Hack for CFO role

Editas Medicine
Dr. Andrew Hack
was named CFO.

Genome editing outfit Editas Medicine has found its new CFO in Dr. Andrew Hack, who was formerly a portfolio manager at Millennium Management, operating a healthcare fund focused on biotech, pharma and med tech. Editas CEO Katrine Bosley said Hack's experience "will be invaluable as we continue to build Editas Medicine into a leading genome editing company." Hack called genome editing "the next great frontier in medicine," and said that he is "excited to join Editas, a pioneering genomic medicine company with such a strong financial and scientific foundation, as we start to advance the development of its CRISPR/Cas9 technology into therapeutics that will have a far-reaching impact for a wide range of genetically-driven diseases." Release


Biogen is building a $1B plant, adding 400 jobs in Switzerland. Story

Transgene is shedding 120 jobs to save cash and get its pipeline moving. Story

Allergan, which tracks its roots to Iceland, is closing a plant there. Story


Biotech

> NuCana appointed Chris McGuigan as chief scientific officer. Release

> Inocrin named Charles Osborne Jr. as chief financial officer. Release

> Voyager Therapeutics added Perry Karsen to its board of directors. Release

> Sarepta ($SRPT) appointed Henri Termeer as advisor to the company. Release

> Merganser Biotech appointed Remy Sukhija as chief operating officer. Release

> Mission Therapeutics added Colin Goddard to its board of directors. Release

> Joseph Krivulka and Martin Simonetti joined Prismic Pharmaceuticals' board of directors. Release

> CAS Medical Systems ($CASM) elected Alan Milinazzo to its board of directors. Release

> Insulet ($PODD) promoted Mark Licari to VP of global manufacturing and operations and recruited David Colleran as VP and general counsel. COO Patrick Ryan has resigned. Release

Collegium ($COLL) hired John "Jack" Weet as VP of regulatory affairs and quality assurance. Release

> William Haskel joined Paratek Pharma as senior vice president, general counsel and corporate secretary. Release

> Bellerophon Therapeutics ($BLPH) appointed Amit Agrawal as chief operating officer and Dr. Naseem Amin as independent director of the company. Release

> Innocoll ($INNL) named Jose Carmona as chief financial officer. Release

> Strand Life Sciences appointed Scott Storrer as CEO. Release

Flamel Technologies ($FLML) appointed Sandy Hatten as its senior vice president of quality and regulatory affairs and Gregory Davis as its vice president of business and corporate development. Release

Torsten Hoffmann joined Proteros Biostructures as its chief scientific officer. Release

vTv brought on Rudy Howard as its chief financial officer. Release

Marathon Pharmaceuticals named Joe Nolan its chief commercial officer. Release

Yixin Wang joined DeNovo Sciences as the company's chief scientific officer. Release

Catalyst Pharmaceuticals ($CPRX) appointed Dr. Gary Ingenito as its chief medical officer. Release

Genisphere appointed Thomas Bliss as its new CEO. Release

Vaccines

Vaccibody appointed Martin Bonde as its CEO. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.